Since the spread of COVID-19, or the novel coronavirus, took over the globe, there has been a race in the medical community to find a vaccine and ultimately a cure for the disease. One scientist is coming forward claiming that he has developed a clinical treatment to help patients with severe COVID-19 symptoms that can help to effectively combat the spread of the virus.
Cuthbert Simpkins, MD, is a physician-scientist and the founder of Vivacelle Bio Inc., a clinical-stage biotechnology firm that develops products for critically ill patients. He says that his firm has developed a clinical treatment called VBI-S to treat COVID-19 patients by increasing their oxygen levels.
According to Dr. Simpkins, 70% of deaths of COVID-19 patients are due to septic shock, which is a result of a lack of oxygen. Using this information, he began to develop a new clinical treatment, VBI-S, that could save thousands of lives. This comes at a critical time when standard treatments have been failing.
“It is fulfilling to serve both as a critical care physician providing direct care to COVID patients and as a scientist whose invention could rescue people who are dying of this disease,” says Dr. Simpkins according to Black News.
However, while intravenous infusion of the treatment has demonstrated encouraging preliminary results in a Phase 2a clinical study, Dr. Simpkin’s invention is still currently an experimental drug with more phases to go. Experts say the results give hope that better treatments are on the way.
“I am greatly encouraged that Vivacelle Bio through its innovative discoveries has proposed therapeutic solutions for the most critically ill patients,” said Mallory Williams MD, MPH Chief of Trauma and Critical Care and Director of the Surgical Intensive Care Unit at Howard University Hospital.
“Severe sepsis claims the lives of over 250,000 Americans and 10 million globally each year and now there is a reason to believe that we are closer to significantly decreasing this number.”
